Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

Large granular lymphocytic leukemias (LGLLs) are a heterogeneous group of rare chronic lymphoproliferative disorders ...

Large granular lymphocytic leukemias (LGLLs) are a heterogeneous group of rare chronic lymphoproliferative disorders characterized by the clonal ...

New pathways discovered for drugs to act on cells Previously unknown access points in cell membrane proteins have been discovered, enabling laboratory-developed drugs to modify cell function Date ...

Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine ...

Shuai Chen, MD https://orcid.org/0009-0007-8628-4313 Department of Neurology, The People’s Hospital of Zhengzhou University and Henan Provincial People’s Hospital ...

Despite recent advancements, acute myeloid leukemia (AML) remains a therapeutic challenge ... Isolation of human NK and T cells was performed using the human NK cell isolation kit and the human pan T ...

Mangione's lawyer, Karen Friedman Agnifilo, has argued that Mangione can't mount a defense if he has to store all of the 15,000 pages of disclosed prosecution evidence in his New York prison cell.

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...